WAT
Waters Corp
$410.73
장중 · Vol 40.2K · 52주 $282.77–$426.22 · 기준 2026. 8. 21. PM 3:59 ET
일봉 $413.49 · Aug 31, 2026
WAT 가격 추세
종가
$413.49
시가
$405.99
고가
$414.09
저가
$409.90
30초 브리핑
WAT 오늘의 판단 요약
보유 데이터를 비교 가능한 문장으로 해석한 요약입니다.
52주 범위의 89%
연중 고점권입니다. 추세 강도와 돌파 실패 위험을 함께 확인하세요.
Forward P/E 25.1배
선행 P/E가 낮아 시장은 이익 증가를 반영하고 있습니다.
20일 평균의 1.2배
거래량은 최근 평균 범위입니다.
2026-10-30
실적 전후 변동성 확대 가능성이 있으므로 컨센서스 범위와 옵션 기대변동을 함께 보세요.
펀더멘털 기준 Sep 1, 2026 · 규칙 기반 요약이며 투자 조언이 아닙니다.
핵심 통계
WAT 일봉·펀더멘털 스냅샷 기준 주요 지표
펀더멘털 스냅샷 Sep 1, 2026
Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. The company operates through two segments, Waters and TA. The company designs, manufactures, sells, and services liquid chromatography, as well as mass spectrometry (MS) technology systems and supports products, including chromatography columns, and other consumable products. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer goods, and healthcare products, as well as for life science research; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. In addition, the company offers MS technology, which is used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Its products are used by clinical, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company was founded in 1958 and is headquartered in Milford, Massachusetts.
34 Maple Street · Milford, MA, United States · 직원 16,000명
시가총액
$40.71B
Trailing P/E
105.2
최근 12개월 이익 기준
Forward P/E
25.1
이익 증가 기대 반영
EPS (TTM)
$3.94
배당 수익률
—
배당성향
0.0%
베타
1.18
시장과 유사
ROE
1.9%
P/B
2.68
EV/EBITDA
31.5
52주 범위
$282.77 – $426.22
현재 위치 89%
거래량
683.8K
20일 평균 547.1K · 1.2배
애널리스트 의견
매수 71%
총 24명 · 0m
DITM LEAPS Analysis
WAT 장기 DITM 콜옵션을 진입 적합도 순으로 비교
해당 종목의 옵션 데이터가 없습니다.
재무제표
WAT 연간 손익·현금흐름·재무상태
매출 성장률
+7.0%
최근 연간 YoY
EPS 성장률
+0.5%
최근 연간 YoY
영업이익률
25.4%
최근 연간
FCF 마진
17.1%
잉여현금흐름 / 매출
매출 추세
순이익 추세
잉여현금흐름 추세
| 항목 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| 매출 | $3.17B+7.0% | $2.96B+0.1% | $2.96B-0.5% | $2.97B |
| 매출총이익 | $1.88B+6.7% | $1.76B-0.2% | $1.76B+2.2% | $1.72B |
| 영업이익 | $802.59M-4.2% | $837.92M+2.5% | $817.68M-7.4% | $883.19M |
| 순이익 | $642.63M+0.8% | $637.83M-0.7% | $642.23M-9.3% | $707.75M |
| 희석 EPS | $10.76+0.5% | $10.71-1.2% | $10.84-7.6% | $11.73 |
| EBITDA | $1.03B-0.6% | $1.04B+3.5% | $1.00B-1.6% | $1.02B |
| 영업현금흐름 | $652.55M-14.4% | $762.12M+26.4% | $602.81M-1.4% | $611.66M |
| 잉여현금흐름 | $539.81M-12.9% | $619.64M+40.1% | $442.18M+3.3% | $428.20M |
| 총자산 | $5.08B+11.5% | $4.55B-1.6% | $4.63B+41.0% | $3.28B |
| 총부채 | $1.49B-12.4% | $1.70B-30.3% | $2.44B+46.8% | $1.66B |
최신 연도 우선 · 작은 퍼센트는 직전 연도 대비 변화입니다.
캘린더
WAT 실적·배당 일정
매출 하단
$1.75B
EPS 하단
$3.95
매출 상단
$1.76B
실적 발표일
2026-10-30
D-59
EPS 상단
$4.03
매출 컨센서스
$1.75B
EPS 컨센서스
$4.00
배당락일
1996-11-26
10871일 전
뉴스
WAT 관련 최신 기사
제품·기술Is Wall Street Bullish or Bearish on Waters Corporation Stock?
Although Waters Corporation has exceeded the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.
Barchart · Aug 28, 2026
실적Research Tools & Consumables Stocks Q2 Highlights: Waters Corporation (NYSE:WAT)
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Waters Corporation (NYSE:WAT) and the rest of the research tools & consumables stocks fared in Q2.
StockStory · Aug 26, 2026
- 일반
Qiagen names Jonathan Pratt as CEO amid takeover talks
Investing.com -- Qiagen N.V. (NYSE:QGEN) announced Monday that Jonathan M. Pratt will become chief executive officer on September 1, 2026, as the molecular testing company continues discussions with potential buyers.
Investing.com · Aug 24, 2026
실적Agilent Stock Has A Catalyst Coming On August 26 That Investors Should Not Ignore
Agilent Technologies has a company-confirmed earnings report dropping after the close on August 26, and every operating lever heading into that date is pointing the same direction. Here is what retirement-focused investors need to understand before the bell rings.
24/7 Wall St. · Aug 21, 2026
실적1 Unpopular Stock That Deserves a Second Chance and 2 That Underwhelm
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.
StockStory · Aug 18, 2026
- 실적
The 5 Most Interesting Analyst Questions From Waters Corporation’s Q2 Earnings Call
Waters Corporation’s Q2 results were met with a positive market reaction, driven by strong organic growth and momentum from its recently acquired Biosciences and Diagnostic Solutions businesses. Management pointed to robust demand across pharmaceutical, academic, and government markets, as well as the successful integration of new product launches. CEO Udit Batra highlighted that, "GLP-1 testing part of the business grew over 40% this quarter," with broad-based contributions across regions. The
StockStory · Aug 13, 2026
실적Waters (WAT) Q2 2026 Earnings Call Transcript
Organic growth accelerated to 9% as acquired units and legacy markets recovered.
Motley Fool · Aug 11, 2026
- 제품·기술
1 Surging Stock with Competitive Advantages and 2 We Turn Down
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.
StockStory · Aug 10, 2026
- 실적
Waters Q2 Earnings Call Highlights
Waters (NYSE:WAT) reported second-quarter 2026 revenue of $1.645 billion, driven by 9% organic constant-currency growth and a 4% increase in revenue from its acquired Biosciences and Diagnostic Solutions businesses. The company raised its full-year outlook for organic revenue, acquired-business reve
MarketBeat · Aug 9, 2026
- 제품·기술
Waters (WAT) Launches Xevo TQ Absolute XR IVD For Clinical Labs
Waters (NYSE: WAT) introduced the Xevo TQ Absolute XR IVD Mass Spectrometer, a new clinical laboratory system with high analytical sensitivity and robustness. The instrument targets critical clinical applications, including hormone testing and toxicology workflows. The launch expands Waters' clinical diagnostics product lineup at a time when demand for precise mass spectrometry tools in healthcare remains a key focus for laboratories. Consider exploring other companies supplying the tools...
Simply Wall St. · Aug 8, 2026
홀더
WAT 내부자·기관 보유 현황
최신 보고 목록 기준이며 실제 거래 시점과 보고일 사이에는 시차가 있습니다.
기관 보유
102.3%
기관 보유 (유동주식)
102.4%
내부자 보유
0.1%
기관 수
1,618
주요 기관 홀더
| 홀더 | 주식 수 | 평가액 | 지분 | 변동 | 보고일 |
|---|---|---|---|---|---|
| Blackrock Inc. | 8.48M | $3.52B | 8.6% | -0.7% | Jun 30, 2026 |
| Vanguard Capital Management LLC | 6.42M | $2.66B | 6.5% | 0.6% | Jun 30, 2026 |
| Vanguard Portfolio Management LLC | 4.74M | $1.97B | 4.8% | -0.3% | Jun 30, 2026 |
| Massachusetts Financial Services Co. | 4.63M | $1.92B | 4.7% | -0.1% | Jun 30, 2026 |
| State Street Corporation | 4.38M | $1.82B | 4.5% | 0.5% | Jun 30, 2026 |
| T. Rowe Price Investment Management, Inc. | 3.82M | $1.58B | 3.9% | -18.1% | Jun 30, 2026 |
| Invesco Ltd. | 3.49M | $1.45B | 3.6% | 61.2% | Jun 30, 2026 |
| Alliancebernstein L.P. | 2.69M | $1.12B | 2.7% | 27.3% | Jun 30, 2026 |
| Geode Capital Management, LLC | 2.64M | $1.09B | 2.7% | -0.4% | Jun 30, 2026 |
| Fundsmith LLP | 2.27M | $942.72M | 2.3% | -29.2% | Jun 30, 2026 |
면책조항: 증시가격은 모든 주식 시장의 최신 증시가격을 표시하는 것은 아니며, 정보가 지연되거나 잘못될 수 있습니다. 거래 목적이나 조언이 아닌 정보 제공 목적으로만 제공됩니다.
.png&w=3840&q=75)